Heart failure
Introduction
MicroRNAs (miRNAs) are endogenous small RNAs that are 21e25 nucleotides in length. 1 Dysregulation of intracellular miRNA expression has been described in various diseases, including a number of cardiovascular conditions. 2 Many studies have indicated that miRNAs are detectable and highly stable in plasma and other biological fluids. Furthermore, Abbreviations: AUC, area under the receivereoperator characteristic curve; NT-proBNP, N-terminal pro-brain natriuretic peptide; DCM, dilated cardiomyopathy; EF, ejection fraction; HF, heart failure; miRNA, microRNA; ROC, receivereoperator characteristic.levels of circulating miRNAs have been shown to correlate with disease, thereby suggesting that miRNAs, might be valuable diagnostic biomarkers. 2 Previous reports demonstrated a potential pathophysiological link between expression of miRNAs (miR-126, miR-155, miR-146a) and immune response for humans with dilated cardiomyopathy (DCM). 3, 4 Other studies showed up-regulated expression of miR-423-5p and miR-361-5p in DCM myocardium. 5 The purpose of this study was to characterize levels of cardiac-associated miRNAs in the circulation of DCM patients and to determine their value as biomarkers for DCM.
Materials and methods

Participants
We recruited 45 DCM patients with New York Heart Association (NYHA) function classes IeIV, and a control group of 39 healthy age-and gender-matched volunteers, at the First Affiliated Hospital (Nanjing Medical University) after obtaining their written informed consent. Inclusion criteria for the DCM group were: a left ventricular ejection fraction (LVEF) less than 45%, as determined by two-dimensional and Doppler echocardiography (GE Vivid VII scanner with 1.7e3.4 MHz transducers); Exclusion criteria were: coronary heart disease (stenosis >50% of the luminal diameter in a major branch), as judged by coronary angiography; arterial hypertension (>160/ 100 mmHg); primary valvular heart disease; cardiomyopathy secondary to any systematic disease; clinical, sustained and rapid supraventricular arrhythmias; pericardial diseases; congenital heart diseases; cor pulmonale. 6 Inclusion criteria for the control group were: absence of known coronary, valvular, or myocardial disease. Exclusion criteria for all participants were: pregnancy, dialysis, and known or treated malignancies. The Institutional Review Board of the First Affiliated Hospital approved the study protocol.
N-terminal pro-brain natriuretic peptide (NTproBNP) measurements
NT-proBNP was measured using an electrochemiluminescence immunoassay (E170 Roche Diagnostics, Mannheim, Germany).
2.3.
Plasma RNA purification
Blood samples were collected in tubes containing EDTA (Gong Dong EDTA K 2 ), and plasma was isolated by centrifugation at 1500 Âg for 15 min at 4 C. Total RNA was isolated from 400 mL of plasma using the mirVana PARIS kit (AM1556, Ambion) according to the manufacturer's instructions. Before RNA isolation, 25 fmol of synthetic Caenorhabditis elegans MicroRNA-39 (cel-miRNA-39; Qiagen, Germany) was added to the mixture as an internal reference. 7 RNA isolated from plasma was subsequently re-suspended in 100 mL of RNasefree water, and then stored at À80 C.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Reverse transcription of miRNAs was performed using the TaqMan Ò MicroRNA Reverse Kit (Applied Biosystems, Foster, CA) according to the manufacturer's recommendations. The 15 mL RT reaction system contained 5 mL of RNA extract, 0.15 mL of 100 mM dNTPs (with dTTP), 1 mL of multiscribe reverse transcriptase (50 U/mL), 1.5 mL of 10 Â RT buffer, 0.19 mL of RNase inhibitor (20 U/mL), 4.16 mL of RNase-free water, and 3 mL of 5 Â miRNA-specific stem-loop RT primer (Applied Biosystems, Foster, CA 
Results
No significant differences in the clinical characteristics of the study populations were observed ( Fig. 3 95% confidence interval 0.555e0.793). By using a threshold miR-423-5PLnRQ of 4.017 as the lower limit for patients with DCM, there was a sensitivity of 87% and a specificity of 49% for patients with DCM patients.
Discussion
Previous reports demonstrated a potential pathophysiologic link between expression of miRNAs (miR-126, miR-155, miR146a) and immune response in human DCM. 3, 4 It was also demonstrated that circulating levels of some miRNAs were indices of patients with HF, 9,10 although there was limited 
evaluation of levels in patients with DCM. We did not confirm dysregulation of miR-126 and miR-361-5P plasma levels in DCM patients, in contrast to reports of patients with ischemic heart disease by Fukushima and Chen. 11, 12 This difference may be explained, in part, by decreased expression of miR-126 in diabetes mellitus and coronary heart disease. 13, 14 In addition, elevated expression of miR-361-5p is associated with metastatic colorectal cancer, 15 whereas its involvement in heart failure is undetermined. Thomas Thum's study demonstrated up-regulated expression of miR-423-5p in DCM myocardium. 5 In addition, Tijsen et al. found that miR-423-5p was able to distinguish heart failure from healthy controls and patients with dyspnea attributable to other causes (with an area under the curve of 0.91). 9 Similarly, Yaron Goren reported that plasma levels of miR-423-5p were higher in HF patients than in controls. 10 A possible mechanism for this is that expression of miR-423-5P in cell is up-regulated by ANP. 16 We also found that miR-423-5p mean plasma levels were significantly higher in DCM patients than in healthy subjects, but the degree of increase and diagnostic value are conspicuously lower than for the previous studies. This may be because the previous studies included ischemic heart disease. This is supported by Tutarel's data, that patients with reduced systemic right ventricle ejection fraction miR-423-5p levels were not elevated. 17 Consequently, microRNA levels associated with different categories of heart failure may vary. Therefore, further studies are needed to evaluate the diagnostic value of miR-423-5P levels in plasma to identify patients with heart failure. Our study showed that miR-423-5p levels are also positively related to NT-proBNP levels in patients with DCM. Similarly, Tijsen demonstrated a correlation between the plasma levels of miR-423-5p and NT-proBNP. 9 Consequently, circulating levels of miR-423-5p may reflect the severity of DCM. MiR-146a and miR-155 are immunity-associated miRNAs that may contribute to the development of heart failure. 18 Prior studies showed that miR-146a and miR-155 levels are increased in the myocardium of heart failure patients. 4, 19 Corsten showed that inflammation-miRNA-155 plays a central role in the induction of cardiac inflammation and failure. 20 Our study showed no dysregulation in the plasma levels of miR-146a and miR-155 in patients with DCM. We suspect that these two miRNAs are sufficiently localized that any variation in myocardial levels is not detectable in plasma. There are several limitations to this study. Although our cohort of participants is relatively large when compared with previous miRNAs studies, one of the major limitations of this study is sample size. Secondly, we have not completed longterm follow-ups of patients. Consequently, the potential for miR-423-5p to be served as prognostic indicator for DCM needs to be studied.
In conclusion, our results suggest that patients with dilated cardiomyopathy have elevated plasma levels of miR-423-5p. In addition, plasma concentration of miR-423-5p may reflect the severity of DCM. The potential for miR-423-5P to discriminate between heart failure caused by DCM patients and healthy people warrants further investigation in larger populations. Plasma levels of immunity-associated miR-146a, -155, and -126 were not significantly different between DCM and healthy groups. 3 e Diagnostic accuracy of miRNA-423-5p. A receivereoperator characteristic (ROC) curve was established to determine the diagnostic power for distinguishing DCM cases from healthy people. The area under the curve (AUC) was 0.674 (95% confidence interval 0.555e0.793). Use of a miR-423-5pLnRQ threshold of 4.017 as the lower limit for patients in the DCM group, resulted in a sensitivity of 87% and a specificity of 49% for the identification of DCM patients.
